-
Partnering
We selectively pursue strategic partnerships that include technology, product or contract manufacturing opportunities.
In our efforts to develop innovative products for life threatening diseases, we selectively pursue strategic partnerships that include technology or product opportunities. Our partnering initiatives include technology collaborations that would benefit from our PEGylation expertise, as well as product partnerships that are complementary to our areas of therapeutic focus, cancer and other life threatening diseases. We are ideally positioned to offer prospective partners the following credentials:
- A strong technology base that is proven through several clinical stage and marketed products
- The proven ability to bring products from research through development to the marketplace
- Cutting-edge chemistry and microbiology laboratories with isolator technology
- An experienced management team with a track record of successfully developing and commercializing pharmaceutical products.
Search
| (ENZN) NASDAQ | |||
| Last Trade | 9.82 | ||
| Change(%) |  | +0.01 | |
| Volume | 261232 | ||
| 1:15 PM - Mar 09, 2010 | |||
News
-
09-10-2009
Enzon to Present at NewsMakers...
Enzon to Present at NewsMakers in the Biotech Industry Conference
-
07-27-2009
Enzon to Release Second Quarte...
Enzon to Release Second Quarter 2009 Earnings on Tuesday, August 4, 2009; Conference Call and Webcast to Follow
-
07-27-2009
Enzon to Present at BMO Focus...
Enzon to Present at BMO Focus on Healthcare Conference
-
07-23-2009
Enzon Enhances Governance with...
Enzon Enhances Governance with the Addition of a New Non-Executive Chairman and New Independent Director
-
05-14-2009
UCB"s Cimzia® Approved in the...
UCB"s Cimzia® Approved in the U.S. for Adult Patients Suffering from Moderate to Severe Rheumatoid Arthritis
-- Enzon to receive royalties for PEGylation technology-- -
01-21-2009
Enzon Concludes Tender Offer f...
Enzon Concludes Tender Offer for a Portion of Its Debt
-
07-29-2008
Enzon to Release Second Quarte...
Enzon to Release Second Quarter 2008 Earnings on Wednesday, August 6, 2008; Conference Call and Webcast to Follow
-
05-20-2008
Enzon Announces Clinical Data...
Enzon Announces Clinical Data From PEG-SN38 and rhMBL Studies at ASCO -- Company will host reception --
-
05-06-2009
Enzon Reaches Phase II Dose fo...
Enzon Reaches Phase II Dose for PEG-SN38
-- Composition of matter patent granted until 2027-- -
02-13-2009
Enzon to Release Fourth Quarte...
Enzon to Release Fourth Quarter 2008 Earnings on Thursday, February 19, 2009; Conference Call and Webcast to Follow
-
02-04-2009
Enzon to Present at 11th Annua...
Enzon to Present at 11th Annual BIO CEO & Investor Conference
-
10-29-2008
Enzon to Release Third Quarter...
Enzon to Release Third Quarter 2008 Earnings on Wednesday, November 5, 2008; Conference Call and Webcast to Follow